Jacek Glinka will become President of Mylan’s European business on 2 December 2013. He will report to Hal Korman, Chief Operating Officer.
Prior to joining Mylan, Glinka was Chief Executive of the Polpharma Group from 2003 to 2006 and from 2009 to 2013. Under his leadership, Polpharma became a leader in the Polish market and one of the fastest-growing pharmaceutical companies in the region. From 2011 to 2013, Polpharma doubled its revenue to more than US$1bn.
Glinka also led Polpharma in the acquisition and integration of a number of businesses including Chimpharm in Kazakhstan; Polfa Warsaw in Poland; the antibiotics division of Bioton in Poland; and the nutraceuticals portfolio of Herbapol. Additionally, he led the company’s expansion into new geographic regions, both organically and through acquisition, including Kazakhstan, Uzbekistan, Azerbaijan and Vietnam.
Prior to his tenure at Polpharma, Glinka was a Managing Director at Spectra Services. He began his professional career as a strategic management consultant with firms including Deloitte & Touche and A.T. Kearney.
